Although in principle GEP would have been applicable for target selection, attempts failed due to lack of compounds usable for personalized treatment, and suggested compounds like inhibitors of aurora kinase (57, 82) or IGF1R (82, 94) never made it to approval in myeloma. This evidence concerns the gene IGF1R and plasma cell myeloma.